Galectin Reports Q2 Loss of $9.2M, FDA Agreement on Phase 3 Design, and Cash Runway to June 2027
GALT sits 72% above its 52-week low of $2.025.
Summary
Galectin Therapeutics reported a wider Q2 net loss of $9.2 million, driven by a non-cash derivative fair-value charge, and announced FDA agreement on its Phase 3 trial design for belapectin, with protocol submission expected in Q3 2026.
Key Events · Earnings and Guidance · GALT
-
Q2 Net Loss Widens to $9.2M
Net loss applicable to common stockholders was $9.2 million ($0.14/share) for Q2 2026, up from $7.6 million ($0.12/share) in Q2 2025, primarily due to a $3.2 million non-cash charge for change in fair value of derivative liabilities.
-
FDA Agreement on Phase 3 Design
The company reached agreement with the FDA on key elements of the planned Phase 3 trial for belapectin in MASH cirrhosis, including a composite liver outcome primary endpoint, blinded central review, and a single 2 mg/kg LBM dose. Protocol submission is expected in Q3 2026.
-
Cash Runway Through June 2027
As of June 30, 2026, cash and cash equivalents were $13.2 million, with an additional $10 million available under a line of credit from the Chairman. Management believes this is sufficient to fund planned operations through June 2027.
-
Debt-to-Equity Conversion Reiterated
The filing reiterates the previously disclosed conversion of approximately $105.8 million in debt and accrued interest by Chairman Richard Uihlein into 34,376,167 shares of common stock, effective July 31, 2026.
Analysis · GALT · Life Sciences
Galectin Therapeutics reported a Q2 2026 net loss of $9.2 million, wider than the $7.6 million loss a year ago, driven by a $3.2 million non-cash charge from the change in fair value of derivative liabilities. The company also announced it reached agreement with the FDA on the key elements of its Phase 3 trial for belapectin in MASH cirrhosis, including the primary endpoint and dose, with protocol submission expected in Q3 2026. Cash of $13.2 million plus a $10 million available line of credit is expected to fund operations through June 2027. The filing reiterates the previously disclosed $105.8 million debt-to-equity conversion by Chairman Richard Uihlein, but the new financial results and regulatory update are material.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GALT was trading at $3.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $356M. The 52-week trading range was $2.03 to $7.13. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.